Free tool
FAERS Monitor: Ceretec
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019829 or its brand name (Ceretec, Technetium Tc-99m Exametazime Kit). Reports on generic versions are filed under their own applications.
Reports
38
Serious
14
37% of reports
Hospitalization
3
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event13
- drug ineffective8
- radioisotope scan abnormal7
- headache4
- rash4
- chills3
- condition aggravated2
- dyspnoea2
- malaise2
- nausea2
- unresponsive to stimuli2
- vasospasm2
- abdominal discomfort1
- anaphylactic reaction1
- autoimmune thyroiditis1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,121 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| radioisotope scan abnormalSignal | 7 | 5540.6 | 2826.1 | 33,098 |
| vasospasm | 2 | 1208.4 | 313.1 | 1,354 |
| autoimmune thyroiditis | 1 | 146.5 | 21.2 | 36 |
| unresponsive to stimuli | 2 | 42.9 | 11.1 | 45 |
| no adverse eventSignal | 13 | 39.7 | 25.6 | 457 |
| chillsSignal | 3 | 14.2 | 4.8 | 25 |
| anaphylactic reaction | 1 | 10.0 | 1.4 | 2 |
| rashSignal | 4 | 5.1 | 2.0 | 10 |
| condition aggravated | 2 | 3.6 | 0.9 | 2 |
| headacheSignal | 4 | 3.5 | 1.4 | 5 |
| drug ineffectiveSignal | 8 | 3.4 | 1.8 | 12 |
| abdominal discomfort | 1 | 3.3 | 0.5 | 0 |
| malaise | 2 | 2.5 | 0.7 | 1 |
| dyspnoea | 2 | 2.0 | 0.5 | 0 |
| nausea | 2 | 1.4 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.